Congress returns from its summer recess Sept. 9 and swift action on Senate compounding legislation could come any time after that. NCPA has strong concerns about the compounding sections of S. 959, especially a proposed overly broad expansion of authority by the Food and Drug Administration over traditional pharmacy compounding. In an op-ed in the Roanoke Times Sept. 1, Keith Hodges, a member of both the NCPA board of directors and Virginia House of Delegates, outlined some of those concerns.
NCPA believes the widely supported electronic pedigree provisions of S. 959 should be split off and enacted on their own while Congress and stakeholders work on compounding legislation that protects public health without preventing patients in need from receiving pharmacist-customized medications.
For your consideration, NCPA has drafted a letter pharmacists can personalize and send to their members of Congress. A suggested letter to the editor of your local paper also is available
